How Did AstraZeneca’s CVMD Franchise Perform in 2014?


Dec. 4 2020, Updated 10:53 a.m. ET

The CVMD franchise

The cardiovascular and metabolic disease (or CVMD) segment is AstraZeneca’s (AZN) largest franchise by revenue. In 2014, the CVMD franchise generated nearly $9.8 billion, a 11% rise in sales as compared to $8.8 billion in 2013. The annual CVMD worldwide market is estimated at $178.6 billion.

AstraZeneca’s CVMD segment is focused on developing life-changing medicines for the following conditions:

  • thrombosis, or blood clotting
  • atherosclerosis, or hardening of arteries
  • dyslipidaemia, or abnormal levels of blood lipids
  • hypertension, or high blood pressure
  • metabolic diseases, including diabetes and related complications
Article continues below advertisement

The need for the CVMD franchise

As per the World Health Organization’s fact sheet updated in January 2015, cardiovascular diseases are the number one cause of deaths globally. Estimates suggest nearly 17.5 million people died of cardiovascular diseases in 2012, while 1.5 million people died of diabetes. The world market for high blood pressure medicines is estimated at $46.0 billion, $29.6 billion for medicines treating abnormal levels of blood cholesterol, and $51.8 billion for diabetes medicines. Therefore, the company is investing heavily in clinical development and lifecycle management of drugs for cardiovascular and renal diseases.

Collaborations in the CVMD franchise

AstraZeneca is engaging in collaborations focused on scientific innovation in the CVMD franchise. Some of the collaborations during 2014 include:

  • collaboration with the Max Planck Institute of Molecular Physiology to create a satellite unit to study areas of new modality chemistry in CVMD and renal diseases
  • collaboration with Mitsubishi Tanabe Pharma Corporation in areas of diabetic nephropathy to validate and progress novel research targets and molecules into clinical development
  • collaboration with the Shanghai Institute of Biological Sciences to study newly formed coronary vessels in CV diseases

Major competitors for the CVMD franchise include Sanofi (SNY), Merck and Co. (MRK), Novartis (NVS), and Pfizer (PFE). Pfizer (PFE) forms about 7.80% of the total assets of the Health Care Select Sector SPDR ETF (XLV).


Latest Health Care Select Sector SPDR® ETF News and Updates

    Market Realist Logo

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.